Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Existing backer Banco Sabadell Venture Capital contributed to a round that will help the stroke surgery device developer fund clinical studies.

Legend Capital returned as the RNA drug developer secured $28.8m in a round co-led by Panlin Capital and Trinity Innovation Fund.

Kooksoondang Brewery took part in a series B round for oncology antibody developer Hummingbird Bioscience as it prepares to move its lead assets into the clinic.

Building on translational science from Stanford, Jasper has secured funding to progress its Amgen-licensed conditioning agent for patients awaiting stem cell transplants.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The cancer drug developer emerged from stealth with $194m in funding, $85m of which was just closed in a round featuring returning investor Roche Venture Fund.

Tufts Health Plan, Henry Ford Health System and Highmark Health all chipped in as care provider Kaiser Permanente's corporate VC unit closed its latest fund.

Gene therapy developer Limelight Bio grew from research at University of Pennsylvania and has landed $75m in its first publicly-disclosed round.

Mac Ventures will receive support from Yeshiva University business school students, making early-stage investments in a number of tech-oriented sectors.